Development and clinical validation of a quantitative mass spectrometric assay for PD-L1 protein in FFPE NSCLC samples

被引：0

作者：

An, E. ^{[1
]}

Liao, W. ^{[1
]}

Thyparambil, S. ^{[1
]}

Rodriguez, J. ^{[2
]}

Salgia, R. ^{[3
]}

Wistuba, I. ^{[2
]}

Burrows, J. ^{[1
]}

Hembrough, T. ^{[1
]}

机构：

[1] OncoPlex Diagnost, Rockville, MD USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Chicago, Chicago, IL 60637 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷

关键词：

D O I：

10.1016/S0959-8049(14)70615-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

489

引用

页码：159 / 159

页数：1

共 50 条

[21] PD-L1/PD-1 Proximity Assay: Witnessing the Real Protein-Protein Interaction
Kombak, Faruk Erdem
Bhanot, Umesh
Tanaka, Asako
Ondrejkovic, Kateryna
Linkov, Irina
Asher, Marina
Murillo, Adrian
Silber, Joachim
Roehrl, Michael
MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1250 - 1251
[22] Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients.
Rebelatto, Marlon
Mistry, Amita
Sabalos, Costi
Walker, Jill
Midha, Anita
Steele, Keith
Robbins, Paul B.
Li, Xia
Shi, Li
Blake-Haskins, John A.
Ibrahim, Ramy A.
Richman, Laura
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[23] Co-amplifications of PD-L1/PD-L2 genes (9p24.1) and PD-L1 protein expression in NSCLC patients
Clave, S.
Casadevall, D.
Pijuan, L.
Rodriguez-Rivera, M.
Garcia-Moreno, P.
Taus, A.
Albanell, J.
Espinet, B.
Arriola, E.
Salido, M.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S58
[24] Distribution of PD-L1 Tumor Expression by Assay Type in Patients with Metastatic NSCLC (MNSCLC)
Velcheti, V.
Cao, X.
Liu, F.
Patwardhan, P.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1779 - S1780
[25] Enhanced patient selection for anti-PD-L1 treatment in metastatic NSCLC with quantitative continuous scoring of PD-L1
Lesniak, Jan Martin
Schick, Markus
Kunzke, Thomas
Pollastri, Federico
Vigueras-Guillen, Juan Pedro
Hessel, Harald
Haneder, Susanne
Sontakke, Pallavi
DaCosta, Karma
Alleze, Regina
Sade, Hadassah
Barrett, J. Carl
Schmidt, Gunter
Stewart, Ross
CANCER RESEARCH, 2024, 84 (06)
[26] PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC
Lau, Sally C. M.
Rabindranath, Madhumitha
Weiss, Jessica
Li, Janice J. N.
Fung, Andrea S.
Mullen, Dorinda
Alshamlan, Najd
Ruff, Heather M.
Tong, Leung Chu B.
Pal, Prodipto
Cabanero, Michael R.
Hsu, Ying-Han R.
Sacher, Adrian G.
Shepherd, Frances A.
Liu, Geoffrey
Bradbury, Penelope A.
Yasufuku, Kazuhiro
Czarnecka-Kujawa, Katarzyna
Ko, Hyang Mi
Tsao, Ming-Sound
Leighl, Natasha B.
Schwock, Joerg
LUNG CANCER, 2022, 171 : 42 - 46
[27] Brightfield Multiplex Immunohistochemistry Assay for PD-L1 Evaluation in Challenging Melanoma Samples
Ugolini, Filippo
Tinunin, Luca
Nozzoli, Filippo
Simi, Sara
Di Gangi, Dario
Baroni, Gianna
Antonini, Pietro
Szumera-Cieckiewicz, Anna
Massi, Daniela
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2024, 32 (08) : 389 - 394
[28] Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients
He, Jiabei
Pan, Yuanqing
Guo, Yang
Li, Baolan
Tang, Yu
JOURNAL OF IMMUNOTHERAPY, 2020, 43 (05) : 156 - 164
[29] PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice
Eguren-Santamaria, Inaki
Sanmamed, Miguel F.
Goldberg, Sarah B.
Kluger, Harriet M.
Idoate, Miguel A.
Lu, Benjamin Y.
Corral, Jesus
Schalper, Kurt A.
Herbst, Roy S.
Gil-Bazo, Ignacio
CLINICAL CANCER RESEARCH, 2020, 26 (16) : 4186 - 4197
[30] Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials
Vallejo, Jonathon
Singh, Harpreet
Larkins, Erin
Drezner, Nicole
Ricciuti, Biagio
Mishra-Kalyani, Pallavi
Tang, Shenghui
Beaver, Julia A.
Awad, Mark M.
ONCOLOGIST, 2024, : 422 - 430

← 1 2 3 4 5 →